Problem of the ‘gold standard’ in biological therapy of rheumatic diseases
Abstract
The history of discovery, learning and contemporary data on the efficacy of genetically engineered drugs from the class of inhibitors of tumor necrosis factor are shown. Due to high efficacy these medicines are widely used in the treatment of such serious diseases as rheumatic arthritis, rheumatoid spondylitis, psoriasis, Crohn>s disease, etc. The spectrum of adverse effects of inhibitors of tumor necrosis factor is less than that of other classes of drugs, and in a number of positions is not different from the population one. Some diseases, such as spondyloarthritis group, have no alternative effective treatment of tumor necrosis factor inhibitors. Can these drugs claim to be the ‘gold standard’ in the treatment of rheumatic diseases? The authors express their point of view on this issue. Keywords: rheumatic arthritis, inhibitors of tumor necrosis factor, infliximab, methotrexate.
About the Authors
A. I. Dubikov
Pacific State Medical University
Russian Federation
Russian Federation
Zh. V. Bondareva
Pacific State Medical University
Russian Federation
Russian Federation
L. A. Levasheva
Pacific State Medical University
Russian Federation
Russian Federation
E. A. Borisenko
Pacific State Medical University
Russian Federation
Russian Federation
References
1. Дубиков А.И. Апоптоз клеток синовиальной оболочки у больных ревматоидным артритом // Тихоокеанский медицинский журнал. 2008. № 4. С. 20-23.
2. Дубиков А.И., Белоголовых Л.А., Медведь Е.Э. Новые возможности применения инфликсимаба при хронических воспалительных ревматических заболеваниях // Выпуск клинических разборов в ревматологической практике. М.: НИИ ревматологии РАмН, 2014. С. 9-14.
3. Дубиков А.И., Дорошевская А.Ю., Кондратовский П.М., Елисейкина М.Г. Белки-регуляторы апоптоза - основа разработки инновационных стратегий лечения ревматоидного артрита (РА) // Бюллетень экспериментальной биологии и медицины. 2013. Т. 156, № 9. С. 355-358.
4. Кассирский И.А., Милевская Ю.Л. Очерки современной клинической терапии. Ташкент: Медицина, 1970. 432 с.
5. Кондратовский П.М., Дубиков А.И., Дорошевская А.Ю., Елисейкина М.Г. Белок PUMA в паттерне регуляторных молекул р53 определяет прогноз больных с лимфопролиферативными заболеваниями // Бюллетень экспериментальной биологии и медицины. 2013. Т. 156, № 12. С. 820-824.
6. Лукина Г.В. Антицитокиновая терапия ревматоидного артрита // Вестник РАМН. 2003. № 7. С. 23-27.
7. Омельяновский В.В., Авксентьева М.В., Крысанов И.С. [и др.] Фармакоэкономический анализ медикаментозной терапии ревматоидного артрита и анкилозирующего спондилита с применением генно-инженерных биологических препаратов. М.: НИИ клинико-экономической экспертизы и фармакоэкономики, 2010.
8. Adalimumab, Etanercept and Nfliximab for the treatment of rheumatoid arthritis // NICE Technology Appraisal Guidance 130. London: NICE, 2010.
9. Brennan F.M., Chantry D., Jackson A. [et al.] Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis // Lancet. 1989. Vol. 2. P. 244.
10. Charles P., Elliott M.J., Davis D. [et al.] Regulation of cytokines, cytokine in rheumatoid arthritis following anti-TNF-{alpha} therapy inhibitors, and acute-phase proteins // J. Immunol. 1999. Vol. 163. P. 1521-1528.
11. Dixon W.G., Watson K., Lunt M. [et al.] Serious infection rates, including site-specific and bacterial intracellular infection rates, in rheumatoid arthritis patients treated with anti-TNFα therapy: results from the British Society for Rheumatology Biologics Register (BSRBR) // Arthritis Rheum. 2006. Vol. 54. P. 2368-2376.
12. Doroshevskaya A.Yu., Kondratovskii P.M., Dubikov A.I., Eliseikina M.G. Apoptosis regulator proteins: basis for the development of innovation strategies for the treatment of rheumatoid arthritis in patients of different age // Bull. Exp. Biol. Med. 2014. Vol. 156, No. 3. P. 377-380.
13. Dubikov A.I. Key molecules regulating apoptosis in rheumatoid arthritis // Int. J. Rheum. Dis. 2014. Vol. 17, Suppl. 2. P. 14.
14. Elewaut D., Matucci-Cerinic M. Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice // Rheumatology. 2009. Vol. 48, No. 9. P. 1114-1121.
15. Elliot M.J., Maini R.N., Feldmann M. [et al.] Randomized doubleblind comparison of chimeric monoclonal antibody to tumor necrosis factor а (cA2) versus placebo in rheumatoid arthritis // Lancet. 1994. Vol. 344. P. 1105-1110.
16. Elliott M.J., Maini R.N., Feldmann M. [et al.] Repeated therapy with monoclonal antibody to tumor necrosis factor alpha (cA2) in patients with rheumatoid arthritis // Lancet. 1994. Vol. 344. P. 1125-1227.
17. Elliott M.J., Maini R.N., Feldmann M. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor а // Arthritis Rheum. 1993. Vol. 36. P. 1681-1690.
18. Feldmann M., Brennan F.M., Maini, R.N. Role of cytokines in rheumatoid arthritis // Annu. Rev. Immunol. 1996. Vol. 14. P. 397.
19. Goekoop-Ruiterman Y.P.M., De Vries-Bouwstra J.K., Allaart C.F. [et al.] Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt Study) // Arthritis Rheum. 2005. Vol. 52. P. 3381-3390.
20. Kay J., Westhovens R. Methotrexate: the gold standard without standardization // Ann. Rheum. Dis. 2009. Vol. 68, No. 7. P. 1081-1082.
21. Klarenbeek N.B., Dirven L., Güler-Yüksel M. [et al.] Clinical and radiological outcomes of Four DAS Driven Treatment Strategies: 6-year results for the BeSt Study // American College of Rheumatology. Philadelphia, PA, 2009. Abstract 1019.
22. Kondratovskii P.M., Dubikov A.I., Doroshevskaya A.Yu., Eliseikina M.G. PUMA protein in p53 regulatory molecule pattern determines the prognosis for patients with lymphoproliferative diseases // Bull. Exp. Biol. Med. 2014. Vol. 156, No. 6. P. 849-853.
23. Lipsky P., van der Heijde D., St.-Clair E.W. [et al.] Infliximab and methotrexate in the treatment of rheumatoid arthritis // N. Engl. J. Med. 2000. Vol. 343. P. 1594-1602.
24. Maini R., St.-Clair E.W., Breedveld F. [et al.] Infliximab (chimeric anti-tumor necrosis factor а monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial // Lancet. 1999. Vol. 354. P. 1932-1939.
25. Monaco C., Nanchahal J., Taylor P. Anti-TNF therapy: past, present and future // Int. Immunol. 2015. Vol. 27, No. 1. P. 55-62.
26. Singh J.A., Christensen R., Wells G.A. [et al.] Biologics for rheumatoid arthritis: an overview of Cochrane Reviews // The Cochrane Library. 2013. Issue 4.
27. Smolen J.S., Landewé R., Breedveld F.C. [et al.] EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs // Ann. Rheum. Dis. 2013. Vol. 73, No. 3. P. 492-509.
28. Souto-Carneiro M., Mahadevan V., Takada K. [et al.] Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor // Arthritis Research & Therapy. 2009. Vol. 11. P. R84.
29. St.-ClairE.W., van der Heijde D.M., Smolen J.S. [et al.] Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial // Arthritis Rheum. 2004. Vol. 50, No. 11. P. 3432-3443.
30. Su L.F., Han A., McGuire H.M. [et al.] The promised land of human immunology. Cold Spring Harb. Symp. // Quant. Biol. 2014. Vol. 78. P. 203.
Review
For citations:
Dubikov A.I., Bondareva Zh.V., Levasheva L.A., Borisenko E.A. Problem of the ‘gold standard’ in biological therapy of rheumatic diseases. Pacific Medical Journal. 2015;(4):17-20. (In Russ.)
Views:
201
Email this article 